Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals
This invention relates to L-tartaric acid complexes, acid addition salts, base addition salts of the compound named (S)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl) morpholine-3-carboxylic acid or tautomer thereof and pharmaceutical compositions thereof, and further relates to use of the compounds or the pharmaceutical compositions in the manufacture of a medicament, especially for use in preventing, managing, treating or lessening a HBV infection. The complex, acid addition salt or base addition salt of the present invention is crystalline form, substantially crystalline form, polymorphism, amorphism, hydrate or solvate.
1. A complex formed from L-tartaric acid and a compound of formula (I) or (Ia):
wherein the complex is L-tartaric acid complex having crystalline form I(A), a mole ratio of the compound of formula (I) or (Ia) to L-tartarate is 1:1 in the crystalline form I(A) of L-tartaric acid complex, and wherein the crystalline form I(A) exhibits the following characteristic X-ray powder diffraction peaks expressed in degrees 2θ at 17.82±0.2°, 19.51±0.2°, 21.61±0.2°, 22.56±0.2°, 23.36±0.2°, 23.54±0.2°, 23.79±0.2° and 31.07±0.2°.
2. The complex of claim 1 , wherein the complex is L-tartaric acid complex having crystalline form I(A), and wherein the crystalline form I(A) exhibits the following characteristic X-ray powder diffraction peaks expressed in degrees 2θ at 9.29±0.2°, 17.82±0.2°, 19.51±0.2°, 20.80±0.2°, 21.61±0.2°, 22.56±0.2°, 23.36±0.2°, 23.54±0.2°, 23.79±0.2° and 31.07±0.2°.
3. The complex of claim 1 , wherein the complex is L-tartaric acid complex having crystalline form I(A), and wherein the crystalline form I(A) exhibits the following characteristic X-ray powder diffraction peaks expressed in degrees 2θ at 7.300°±0.2°, 7.31°±0.2°, 7.61°±0.2°, 9.29°±0.2°, 11.60°±0.2°, 14.69°±0.2°, 15.33°±0.2°, 17.22°±0.2°, 17.82°±0.2°, 18.08°±0.2°, 18.42°±0.2°, 19.51°±0.2°, 20.51°±0.2°, 20.80°±0.2°, 21.61°±0.2°, 22.56°±0.2°, 23.05°±0.2°, 23.36°±0.2°, 23.54°±0.2°, 23.79°±0.2°, 24.39°±0.2°, 24.810°±0.2°, 25.78°±0.2°, 26.07°±0.2°, 27.34°±0.2°, 28.25°±0.2°, 28.87°±0.2°, 29.72°±0.2°, 30.22°±0.2°, 31.07°±0.2°, 31.55°±0.2°, 32.25°±0.2°, 32.85°±0.2°, 33.24°±0.2°, 34.24°±0.2°, 35.03°±0.2°, 35.22°±0.2°, 36.03°±0.2°, 36.88°±0.2°, 37.33°±0.2°, 37.86°±0.2° and 38.36°±0.2°.
4. The complex of claim 1 , wherein the complex is L-tartaric acid complex having crystalline form I(A), and wherein the crystalline form I(A) has a differential scanning calorimetry thermogram comprising an endothermic peak at 186.94° C.±3° C. or 193.78° C.±3° C.; and/or a Raman spectrogram comprising the following absorption peaks at 51, 71, 115, 144, 158, 180, 196, 234, 303, 427, 688, 746, 767, 818, 837, 905, 1001, 1062, 1075, 1128, 1137, 1165, 1179, 1193, 1230, 1269, 1289, 1324, 1337, 1346, 1357, 1401, 1438, 1453, 1477, 1517, 1541, 1607 and 1679 cm −1 , and the error margin of the absorption peaks is ±2 cm −1 .
5. The complex of claim 1 , wherein the complex is L-tartaric acid complex having crystalline form I(A), and wherein the crystalline form I(A) has at least one of following features:
(1) an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 1 ; or
(2) a differential scanning calorimetry thermogram substantially the same as shown in FIG. 2 or FIG. 3 ; or
(3) a Raman spectrogram substantially the same as shown in FIG. 4 .
6. A salt of a compound of formula (I) or (Ia):
wherein the salt is hydrobromide having crystalline form I(C) having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 8 ; and/or a differential scanning calorimetry thermogram substantially the same as shown in FIG. 9 ; or
wherein the salt is mesylate having crystalline form II having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 28 ; and/or a differential scanning calorimetry thermogram substantially the same as shown in FIG. 29 ; or
wherein the salt is amorphous hydrochloride having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 10 ; or
wherein the salt is amorphous benzene sulfonate having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 11 ; or
wherein the salt is amorphous tosilate having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 12 ; or
wherein the salt is amorphous oxalate having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 13 ; or
wherein the salt is amorphous citrate having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 14 ; or
wherein the salt is amorphous maleate having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 15 ; or
wherein the salt is amorphous hydrobromide having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 16 ; or
wherein the salt is amorphous sulfate having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 17 ; or
wherein the salt is amorphous nitrate having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 18 ; or
wherein the salt is amorphous L-tartarate having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 19 ; or
wherein the salt is amorphous salicylate having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 20 ; or
wherein the salt is an amorphous sodium salt having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 23 ; or
wherein the salt is an amorphous calcium salt having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 24 ; or
wherein the salt is an amorphous L-lysine salt having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 25 .
7. A salt of a compound of formula (I) or (Ia):
wherein the salt is hydrobromide having crystalline form I(C), and wherein the crystalline form I(C) exhibits the following characteristic X-ray powder diffraction peaks expressed in degrees 2θ at 20.69±0.2°, 21.61±0.2°, 23.18±0.2°, 24.20±0.2°, 27.09±0.2°, 28.05±0.2°, 28.59±0.2° and 33.13±0.2°; or
wherein the salt is mesylate having crystalline form II, wherein a mole ratio of the compound of formula (I) or (Ia) to mesylate is 3:1 in the crystalline form II, and wherein the crystalline form II exhibits the following characteristic X-ray powder diffraction peaks expressed in degrees 2θ at 8.28°±0.2°, 19.70°±0.2°, 20.00°±0.2°, 24.78°±0.2° and 25.66°±0.2°.
8. The salt of claim 7 , wherein the salt is hydrobromide having crystalline form I(C), and wherein the crystalline form I(C) exhibits the following characteristic X-ray powder diffraction peaks expressed in degrees 2θ at 14.87±0.2°, 20.69±0.2°, 21.61±0.2°, 23.18±0.2°, 24.20±0.2°, 25.38±0.2°, 27.09±0.2°, 28.05±0.2°, 28.59±0.2° and 33.13±0.2°.
9. The salt of claim 7 , wherein the salt is hydrobromide having crystalline form I(C), and wherein the crystalline form I(C) exhibits the following characteristic X-ray powder diffraction peaks expressed in degrees 2θ at 6.29±0.2°, 10.04±0.2°, 10.99±0.2°, 11.83±0.2°, 14.87±0.2°, 15.44±0.2°, 16.05±0.2°, 18.41±0.2°, 18.79±0.2°, 19.12±0.2°, 20.06±0.2°, 20.69±0.2°, 21.30±0.2°, 21.61±0.2°, 22.02±0.2°, 22.93±0.2°, 23.18±0.2°, 23.67±0.2°, 24.20±0.2°, 25.38±0.2°, 26.14±0.2°, 26.73±0.2°, 27.09±0.2°, 27.83±0.2°, 28.05±0.2°, 28.59±0.2°, 29.06±0.2°, 29.92±0.2°, 31.05±0.2°, 31.63±0.2°, 32.29±0.2°, 32.76±0.2°, 33.13±0.2°, 33.63±0.2°, 34.10±0.2°, 34.55±0.2°, 35.42±0.2°, 35.99±0.2°, 36.36±0.2°, 37.02±0.2°, 37.93±0.2°, 38.49±0.2°, 38.72±0.2° and 39.10±0.2°, and/or has a differential scanning calorimetry thermogram comprising an endothermic peak at 158.95° C.±3° C.
10. The salt of claim 7 , wherein the salt is mesylate having crystalline form II, and wherein the crystalline form II exhibits the following characteristic X-ray powder diffraction peaks expressed in degrees 2θ at 8.28° 0.2°, 9.11°±0.2°, 11.36°±0.2°, 17.07°±0.2°, 17.67°±0.2°, 19.70°±0.2°, 20.00°±0.2°, 24.78°±0.2°, 25.66°±0.2° and 26.10°±0.2°.
11. The salt of claim 7 , wherein the salt is mesylate having crystalline form II, and wherein the crystalline form II exhibits the following characteristic X-ray powder diffraction peaks expressed in degrees 2θ at 7.81°±0.2°, 8.28°±0.2°, 9.11°±0.2°, 9.85°±0.2°, 11.36°±0.2°, 12.56°±0.2°, 14.37°±0.2°, 14.72°±0.2°, 15.33°±0.2°, 16.48°±0.2°, 17.07°±0.2°, 17.67°±0.2°, 18.51°±0.2°, 19.70°±0.2°, 20.00°±0.2°, 20.17°±0.2°, 21.17°±0.2°, 21.60°±0.2°, 21.97°±0.2°, 22.47°±0.2°, 22.80°±0.2°, 23.22°±0.2°, 24.10°±0.2°, 24.78°±0.2°, 25.66°±0.2°, 26.10°±0.2°, 26.44°±0.2°, 27.05°±0.2°, 27.48°±0.2°, 28.21°±0.2°, 28.79°±0.2°, 29.60°±0.2°, 30.46°±0.2°, 31.22°±0.2°, 32.89°±0.2°, 33.37°±0.2°, 33.61°±0.2°, 34.39°±0.2°, 35.09°±0.2°, 36.32°±0.2°, 36.94°±0.2°, 37.59°±0.2° and 38.41°±0.2°, and/or has a differential scanning calorimetry thermogram comprising an endothermic peak at 128.26° C.±3° C.
12. A pharmaceutical composition comprising the complex of claim 1 , and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.
13. A method for, managing, treating or lessening an HBV disease in a patient, comprising administering to the patient with a therapeutically effective amount of the complex of claim 1 .
14. The method of claim 13 , wherein the HBV disease is hepatitis B infection or a disease caused by hepatitis B infection; and wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.
15. A pharmaceutical composition comprising the salt of claim 6 , and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.
16. A method for, managing, treating or lessening an HBV disease in a patient, comprising administering to the patient with a therapeutically effective amount of the salt of claim 6 .
17. The method of claim 16 , wherein the HBV disease is hepatitis B infection or a disease caused by hepatitis B infection; and wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.
18. A method for, managing, treating or lessening an HBV disease in a patient, comprising administering to the patient with a therapeutically effective amount of the pharmaceutical composition of claim 12 .
19. The method of claim 18 , wherein the HBV disease is hepatitis B infection or a disease caused by hepatitis B infection; and wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.
20. A method for, managing, treating or lessening an HBV disease in a patient, comprising administering to the patient with a therapeutically effective amount of the pharmaceutical composition of claim 15 .
21. The method of claim 20 , wherein the HBV disease is hepatitis B infection or a disease caused by hepatitis B infection; and wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.
22. A method for managing, treating or lessening an HBV disease in a patient, comprising administering to the patient with a therapeutically effective amount of the salt of claim 7 .
23. The method of claim 22 , wherein the HBV disease is hepatitis B infection or a disease caused by hepatitis B infection; and wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.